Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Zhang, Qiang Bo ^a   Sun, Hui Chuan ^a   Zhang, Ke Zhi ^a   Jia, Qing An ^a   Bu, Yang ^a   Wang, Miao ^a   Chai, Zong Tao ^a   Zhang, Quan Bao ^a   Wang, Wen Quan ^a   Kong, Ling Qun ^a   Zhu, Xiao Dong ^a   Lu, Lu ^a   Wu, Wei Zhong ^a   Wang, Lu ^a   Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SORAFENIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH ACCELERATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG METASTASIS; LYMPHOCYTE COUNT; MALE; METASTASIS POTENTIAL; MOUSE; NATURAL KILLER CELL; NONHUMAN; RECEPTOR DOWN REGULATION; SURVIVAL TIME;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; K562 CELLS; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873652957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055945     Document Type: Article

References (40)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Clavien PA, Petrowsky H, DeOliveira ML, Graf R, (2007) Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 356: 1545-1559.
3. Carr BI, (2004) Hepatocellular carcinoma: current management and future trends. Gastroenterology 127: S218-224.
4. Johnson P, Billingham L, (2009) Sorafenib for liver cancer: the horizon broadens. Lancet Oncol 10: 4-5.
5. Palmer DH (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 2498; author reply 2498-2499.
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
8. Shao YY, Lu LC, Cheng AL, Hsu CH, (2011) Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy. Oncologist 16: 82-86.
9. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
10. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
11. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, et al. (2008) Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111: 5610-5620.
12. Krusch M, Salih J, Schlicke M, Baessler T, Kampa KM, et al. (2009) The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol 183: 8286-8294.
13. Zhao W, Gu YH, Song R, Qu BQ, Xu Q, (2008) Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 22: 1226-1233.
14. Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, et al. (2009) Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 100: 1111-1119.
15. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S, (2008) Functions of natural killer cells. Nat Immunol 9: 503-510.
16. Levy EM, Roberti MP, Mordoh J, (2011) Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011: 676198.
17. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K, (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356: 1795-1799.
18. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, et al. (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 95: 7556-7561.
19. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
20. Borg C, Terme M, Taieb J, Menard C, Flament C, et al. (2004) Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114: 379-388.
21. Wai LE, Fujiki M, Takeda S, Martinez OM, Krams SM, (2008) Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation 85: 145-149.
22. Yang BW, Liang Y, Xia JL, Sun HC, Wang L, et al. (2008) Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice. Eur J Gastroenterol Hepatol 20: 1077-1084.
23. Andrews P, Zhao X, Allen J, Li F, Chang M, (2008) A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol 61: 203-214.
24. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, et al. (2010) Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 16: 3420-3430.
25. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, et al. (2005) AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A 102: 1104-1109.
26. Chiu TL, Lin SZ, Hsieh WH, Peng CW, (2009) AAV2-mediated interleukin-12 in the treatment of malignant brain tumors through activation of NK cells. Int J Oncol 35: 1361-1367.
27. Nokihara H, Yanagawa H, Nishioka Y, Yano S, Mukaida N, et al. (2000) Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice. Cancer Res 60: 7002-7007.
28. Moretta A, Poggi A, Pende D, Tripodi G, Orengo AM, et al. (1991) CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta. J Exp Med 174: 1393-1398.
29. Dennehy KM, Klimosch SN, Steinle A, (2011) Cutting edge: NKp80 uses an atypical hemi-ITAM to trigger NK cytotoxicity. J Immunol 186: 657-661.
30. Wei S, Gamero AM, Liu JH, Daulton AA, Valkov NI, et al. (1998) Control of lytic function by mitogen-activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: identification of perforin and granzyme B mobilization by functional ERK2. J Exp Med 187: 1753-1765.
31. Zimmer J, Andres E, Hentges F (2005) NK cell subsets and CD107a mobilization assay. Leukemia 19: 1849-1851; author reply 1857.
32. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM, (2000) In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A 97: 2731-2736.
33. Cao M, Xu Y, Youn JI, Cabrera R, Zhang X, et al. (2011) Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model. Lab Invest.
34. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, et al. (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12: 426-437.
35. Trotta R, Puorro KA, Paroli M, Azzoni L, Abebe B, et al. (1998) Dependence of both spontaneous and antibody-dependent, granule exocytosis-mediated NK cell cytotoxicity on extracellular signal-regulated kinases. J Immunol 161: 6648-6656.
36. Wei S, Gilvary DL, Corliss BC, Sebti S, Sun J, et al. (2000) Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway. J Immunol 165: 3811-3819.
37. Taguchi Y, Kondo T, Watanabe M, Miyaji M, Umehara H, et al. (2004) Interleukin-2-induced survival of natural killer (NK) cells involving phosphatidylinositol-3 kinase-dependent reduction of ceramide through acid sphingomyelinase, sphingomyelin synthase, and glucosylceramide synthase. Blood 104: 3285-3293.
38. Oh SJ, Erb HH, Hobisch A, Santer FR, Culig Z, (2012) Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr Relat Cancer 19: 305-319.
39. Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, et al. (2011) Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J Hepatol 55: 1041-1048.
40. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.